Slide 1: Q1 2026 presentation
Q1 2026 presentation Webcast 4 May 2026
Slide 2: Agenda and presenters
2 Webcast 4 May 2026 Agenda and presenters • Q1 highlights • Sales regions • Product lines • Q1 financials • Peanut phase 2 results President & CEO EVP, Group CFO VP, Head of IR • Strategic advancements Peter Halling Claus Steensen Sølje Per Plotnikof • 2026 outlook • Q&A session This presentation c
Slide 3: Q1 highlights
3 Webcast 4 May 2026 Q1 highlights Strong tablet sales leading to upgraded full-year outlook Q1 performance Revenue DKKm • Commercial momentum continued across regions and products 2,000 +18% 20% • EBIT boosted by sales growth, gross margin, and scale benefits 1,500 15% 1,000 10% 500 5% Strategy exe
Slide 4: Continued double-digit growth in all sales regions
4 Webcast 4 May 2026 Continued double-digit growth in all sales regions Broad-based momentum driven by growing patient and prescriber bases Europe North America International markets 74% 14% 12% Double-digit growth in most markets Growth fueled by tablets in Canada Growth reflecting timing of shipme
Slide 5: Tablets and anaphylaxis as key growth drivers
5 Webcast 4 May 2026 Tablets and anaphylaxis as key growth drivers Paediatric indications increasingly contributing to tablet growth Anaphylaxis Tablets SCIT/SLIT-drops & other products 57% 32% 11% Paediatric tablets now in most key Higher shipments to China; continued Growth boosted by Jext®; neffy
Slide 6: Higher earnings and strong cash flow
6 Webcast 4 May 2026 Higher earnings and strong cash flow Profitability mainly driven by sales growth and favourable mix Gross profit DKK million 3M 2026 3M 2025 Change DKKm +2pp. 1.500 70% Revenue 1,771 1,522 +18% 1.000 65% Gross profit 1,228 1,016 60% 500 Gross margin 69% 67% 0 55% Q1-25 Q2-25 Q3-
Slide 7: Successful ph 2 peanut tablet trial
7 Webcast 4 May 2026 Successful ph 2 peanut tablet trial Picture with ALLIANCE results: First proof-of-concept for ALK's tablet technology in food allergy family at table eating food Trial success: Dose-dependent efficacy after six months, across all age groups Strong safety profile: Well-tolerated,
Slide 8: Progress with Allergy+ execution
8 Webcast 4 May 2026 Progress with Allergy+ execution Strong momentum continued with paediatric tablets Respiratory allergy • Paediatric tablets launched in 21 countries for HDM and in 13 for tree • +4,000 paediatric tablet prescribers supporting inflow of new patients • ACARIZAX® phase 3 recruitmen
Slide 9: 2026 outlook upgraded
9 Webcast 4 May 2026 2026 outlook upgraded Strong momentum with tablet sales and improved risk profile Revenue Key assumptions 13-16% DKKm Revenue Growth in l.c. • Volume-driven growth across regions and product groups 8.000 20% • Double-digit growth in tablet sales 15% 6.000 Growth in • SCIT/SLIT-d
Slide 10: Q&A session
Q&A session
Slide 11: Upcoming events & Financial Calendar
11 Webcast 4 May 2026 Upcoming events & Financial Calendar Upcoming events: Financial Calendar: 6 May Copenhagen Roadshow 20 August Six-month interim report (Q2) 12 May London Roadshow 18 November Nine-month interim report (Q3) 13 May Milan Roadshow 27 May Frankfurt Roadshow 28 May DNB Carnegie Heal